| Year |
Citation |
Score |
| 2023 |
Chervin AS, Stone JD, Konieczna I, Calabrese KM, Wang N, Haribhai D, Dong F, White MK, Rodriguez LE, Bukofzer GT, Ellis PA, Cosgrove C, Hecquet C, Clarin JD, Palma JP, et al. ABBV-184: A novel survivin-specific TCR/CD3 bispecific T cell engager is active against both solid tumor and hematological malignancies. Molecular Cancer Therapeutics. PMID 37294945 DOI: 10.1158/1535-7163.MCT-22-0770 |
0.617 |
|
| 2015 |
Mattis DM, Chervin AS, Ranoa DR, Kelley SL, Tapping RI, Kranz DM. Studies of the TLR4-associated protein MD-2 using yeast-display and mutational analyses. Molecular Immunology. 68: 203-12. PMID 26320630 DOI: 10.1016/J.Molimm.2015.08.008 |
0.542 |
|
| 2015 |
Sharma P, Wang N, Chervin AS, Quinn CL, Stone JD, Kranz DM. A Multiplex Assay for Detection of Staphylococcal and Streptococcal Exotoxins. Plos One. 10: e0135986. PMID 26305471 DOI: 10.1371/Journal.Pone.0135986 |
0.539 |
|
| 2014 |
Stone JD, Harris DT, Soto CM, Chervin AS, Aggen DH, Roy EJ, Kranz DM. A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control. Cancer Immunology, Immunotherapy : Cii. 63: 1163-76. PMID 25082071 DOI: 10.1007/S00262-014-1586-Z |
0.82 |
|
| 2013 |
Chervin AS, Stone JD, Soto CM, Engels B, Schreiber H, Roy EJ, Kranz DM. Design of T-cell receptor libraries with diverse binding properties to examine adoptive T-cell responses. Gene Therapy. 20: 634-44. PMID 23052828 DOI: 10.1038/Gt.2012.80 |
0.786 |
|
| 2013 |
Soto CM, Stone JD, Chervin AS, Engels B, Schreiber H, Roy EJ, Kranz DM. MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR. Cancer Immunology, Immunotherapy : Cii. 62: 359-69. PMID 22926060 DOI: 10.1007/S00262-012-1336-Z |
0.777 |
|
| 2012 |
Engels B, Chervin AS, Sant AJ, Kranz DM, Schreiber H. Long-term Persistence of CD4(+) but Rapid Disappearance of CD8(+) T Cells Expressing an MHC Class I-restricted TCR of Nanomolar Affinity. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 652-660. PMID 28160633 DOI: 10.1038/mt.2011.286 |
0.777 |
|
| 2012 |
Stone JD, Chervin AS, Schreiber H, Kranz DM. Design and characterization of a protein superagonist of IL-15 fused with IL-15Rα and a high-affinity T cell receptor. Biotechnology Progress. 28: 1588-97. PMID 22961781 DOI: 10.1002/Btpr.1631 |
0.64 |
|
| 2012 |
Engels B, Chervin AS, Sant AJ, Kranz DM, Schreiber H. Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 652-60. PMID 22233579 DOI: 10.1038/Mt.2011.286 |
0.792 |
|
| 2012 |
Stone JD, Chervin AS, Aggen DH, Kranz DM. T cell receptor engineering. Methods in Enzymology. 503: 189-222. PMID 22230570 DOI: 10.1016/B978-0-12-396962-0.00008-2 |
0.797 |
|
| 2012 |
Aggen DH, Chervin AS, Schmitt TM, Engels B, Stone JD, Richman SA, Piepenbrink KH, Baker BM, Greenberg PD, Schreiber H, Kranz DM. Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains. Gene Therapy. 19: 365-74. PMID 21753797 DOI: 10.1038/Gt.2011.104 |
0.767 |
|
| 2011 |
Stone JD, Artyomov MN, Chervin AS, Chakraborty AK, Eisen HN, Kranz DM. Interaction of streptavidin-based peptide-MHC oligomers (tetramers) with cell-surface TCRs. Journal of Immunology (Baltimore, Md. : 1950). 187: 6281-90. PMID 22102724 DOI: 10.4049/Jimmunol.1101734 |
0.734 |
|
| 2011 |
Stone JD, Aggen DH, Chervin AS, Narayanan S, Schmitt TM, Greenberg PD, Kranz DM. Opposite effects of endogenous peptide-MHC class I on T cell activity in the presence and absence of CD8. Journal of Immunology (Baltimore, Md. : 1950). 186: 5193-200. PMID 21451107 DOI: 10.4049/Jimmunol.1003755 |
0.794 |
|
| 2011 |
Aggen DH, Chervin AS, Insaidoo FK, Piepenbrink KH, Baker BM, Kranz DM. Identification and engineering of human variable regions that allow expression of stable single-chain T cell receptors. Protein Engineering, Design & Selection : Peds. 24: 361-72. PMID 21159619 DOI: 10.1093/Protein/Gzq113 |
0.744 |
|
| 2009 |
Chervin AS, Stone JD, Bowerman NA, Kranz DM. Cutting edge: inhibitory effects of CD4 and CD8 on T cell activation induced by high-affinity noncognate ligands. Journal of Immunology (Baltimore, Md. : 1950). 183: 7639-43. PMID 19923452 DOI: 10.4049/Jimmunol.0901664 |
0.797 |
|
| 2009 |
Chervin AS, Stone JD, Holler PD, Bai A, Chen J, Eisen HN, Kranz DM. The impact of TCR-binding properties and antigen presentation format on T cell responsiveness. Journal of Immunology (Baltimore, Md. : 1950). 183: 1166-78. PMID 19553539 DOI: 10.4049/Jimmunol.0900054 |
0.809 |
|
| 2009 |
Stone JD, Chervin AS, Kranz DM. T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology. 126: 165-76. PMID 19125887 DOI: 10.1111/J.1365-2567.2008.03015.X |
0.748 |
|
| 2008 |
Chervin AS, Aggen DH, Raseman JM, Kranz DM. Engineering higher affinity T cell receptors using a T cell display system. Journal of Immunological Methods. 339: 175-84. PMID 18854190 DOI: 10.1016/J.Jim.2008.09.016 |
0.826 |
|
| 2007 |
An J, Chervin AS, Nie A, Ducoff HS, Huang Z. Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor. Oncogene. 26: 652-61. PMID 16909121 DOI: 10.1038/Sj.Onc.1209830 |
0.301 |
|
| Show low-probability matches. |